King's College London

Research portal

Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies.

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)15-20
JournalJournal of Reproductive Immunology
Early online date29 Sep 2017
Publication statusPublished - Nov 2017


King's Authors


Pre-eclampsia is a disease of pregnancy affecting 5%–8% of all pregnancies and leading cause of maternal and fetal mortality. Despite improvements in the diagnosis, there is no effective method of prevention and treatment. While studies in women are of critical importance, investigation of pathological mechanisms in pregnant women is necessarily limited, and the ability to establish cause and effect relationships, difficult. Mouse models have been instrumental in defining pathogenic mechanisms in preeclampsia and in the identification of statins as a potential treatment to prevent pregnancy complications associated with placental dysfunction. Numerous epidemiological studies provided robust evidence demonstrating that pravastatin exposure during pregnancy does not affect fetal development. In addition, pravastatin is hydrophilic and has a limited passage through the placenta, diminishing any safety concerns. Several pilot studies suggest that pravastatin may be a good option to prevent and treat preeclampsia in women. While these studies are promising, the effectiveness of pravastatin to treat preeclampsia needs to be confirmed by randomized clinical trials.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454